Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.

Abstract

Trastuzumab (Herceptin) is a humanised monoclonal antibody used in the treatment of breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2), which is associated with clinically aggressive disease and a poor prognosis. The addition of intravenous trastuzumab to first-line chemotherapy improved the time to disease progression… (More)

Topics

Cite this paper

@article{Plosker2006TrastuzumabAR, title={Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.}, author={Greg L. Plosker and Susan J. Keam}, journal={Drugs}, year={2006}, volume={66 4}, pages={449-75} }